HASBROUCK HEIGHTS, N.J., Feb. 18, 2009 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today that the Company has recently concluded a positive and productive EOP2 meeting with the FDA concerning the Phase 3 program for NX-1207, the Company's investigational drug for benign prostatic hyperplasia (BPH). The pivotal Phase 3 trials for NX-1207 that are being undertaken will incorporate the specific protocol design recommendations provided to the Company by the FDA.
